Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Completed Initiated Sep 25, 2023 (3 years ago)

Brexafemme

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Cross Contamination with Other Products: Potential cross-contamination of ibrexafungerp citrate drug substance with ezetimibe (a non-antibacterial beta-lactam compound).

Cause type: Cross-contamination

Traces of another drug - most often penicillin - got into the product from shared equipment or facilities. Even trace penicillin can trigger a severe allergic reaction in someone who was never meant to receive it. All cross-contamination recalls.

What was recalled

BREXAFEMME (Ibrexafungerp) tablets 150 mg, 4 count cartons, Rx Only, Manufactured for and distributed by SCYNEXIS, Inc., Jersey City, NJ 07302 NDC 75788-115-04

Affected NDC 75788-0115-04

Compare with the code on your package — it is the most precise check available.

Recalling firm
Scynexis, Inc.
NDC code
75788-115-04
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0042-2024 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week. This recall is now completed, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other cross-contamination recalls from 2023

All cross-contamination recalls
Class II · Moderate risk

Alprazolam Tab

CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.

Terminated Cross-contamination Preferred Pharmaceuticals, Inc. NDC 68788-7596-3 D-0506-2023
Class II · Moderate risk

Alprazolam Tab

CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.

Terminated Cross-contamination Preferred Pharmaceuticals, Inc. NDC 68788-7595-3 D-0505-2023
Class II · Moderate risk

Alprazolam Tab

CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.

Terminated Cross-contamination Preferred Pharmaceuticals, Inc. NDC 68788-7594-3 D-0504-2023